Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classement en actions
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prix de l'action
$4.87
Capitalisation boursière
$4.36B
Changement (1 jour)
-5.47%
Changement (1 an)
-15.62%
Pays
CN
Échange Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Catégorie
Healthcare
Ratio P/B pour Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Ratio P/B au October 2026 TTM : 3.43
Selon les derniers rapports financiers et le cours de l'action de Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, le ratio cours/valeur comptable actuel (TTM) est 3.43. À la fin de 2024, le ratio P/B était de 2.38.
Historique du ratio P/B pour Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd de 2006 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 3.43 | 14.17% |
| 2025 | 3.00 | 26.18% |
| 2024 | 2.38 | -14.98% |
| 2023 | 2.80 | 64.60% |
| 2022 | 1.70 | -30.89% |
| 2021 | 2.46 | -23.58% |
| 2020 | 3.22 | -68.02% |
| 2019 | 10.06 | 16.65% |
| 2018 | 8.62 | -11.20% |
| 2017 | 9.71 | -12.75% |
| 2016 | 11.13 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 19.13 | -19.19% |
| 2011 | 23.67 | -9.19% |
| 2010 | 26.07 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.6964 | 95.50% |
US
|
|
| 13.6307 | 297.95% |
US
|
|
| 4.4521 | 29.98% |
AU
|
|
| 4.2241 | 23.32% |
BE
|
|
| 6.3632 | 85.78% |
NL
|
